---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-051121"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2025-04-04T23:59:59+00:00"
generated_at: "2026-05-23T21:04:01.675207+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atara amends Pierre Fabre deal; transfers manufacturing, reduces milestones; eligible for up to $550M

## Summary
- Transferred all manufacturing responsibility for tab-cel to Pierre Fabre as of March 31, 2025; Pierre Fabre will manufacture and supply worldwide at its cost.
- Pierre Fabre assumes remediation costs for third-party facility to address FDA requests and support BLA resubmission for tab-cel.
- Atara reduced certain potential future regulatory and commercial milestone payments in exchange for the accelerated transfer and cost assumption.
- Atara now entitled to aggregate of up to $550M in potential milestones, including up to $40M regulatory milestones for FDA BLA approval; royalties unchanged.

## SEC filing metadata
- accession: 0000950170-25-051121
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2025-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017025051121/0000950170-25-051121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017025051121/atra-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-051121
- JSON: https://secwatch.observer/filing/0000950170-25-051121.json
- Plain text: https://secwatch.observer/filing/0000950170-25-051121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.